Evotec SE (MIL:1EVT)
€ 8.345 0 (0%) Market Cap: 1.52 Bil Enterprise Value: 1.61 Bil PE Ratio: 0 PB Ratio: 1.56 GF Score: 54/100

Q2 2020 Evotec SE Earnings Call Transcript

Aug 12, 2020 / 12:00PM GMT
Operator

Dear, ladies and gentlemen, welcome to the conference call of Evotec SE. At our customers' request, this conference will be recorded. (Operator Instructions) May I now hand you over to Dr. Werner Lanthaler, CEO, who will lead you through this conference. Please go ahead, sir.

Werner Lanthaler
Evotec SE - CEO & Member of Management Board

Good afternoon. This is Werner speaking from sunny Hamburg. Welcome to our half year report 2020. You can find the supporting slides for this call on the web as usual.

We often get asked, what's the purpose of Evotec? And it's very simple. We design and apply innovative technologies and processes across all modalities in order to expand access to more precise medicines together with our partners. Or if you want it, even more simple, we are the drug-discovery and drug-development Autobahn. Especially in times of the pandemic crisis, acceleration and even more speed on this Autobahn is needed today more than ever before.

I'm here together with my team, our CFO, Enno; our COO, Craig; our CSO, Cord, and it's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot